Getein Biotech

Getein Biotech ROCE

The Return on Capital Employed (ROCE) of Getein Biotech (603387.SS) as of Oct 28, 2026 is 8.99 %. In the previous year, Return on Capital Employed (ROCE) was 9.48 % — a change of -5.23% (lower).

ROCE

8.99 %

YoY

-5.23%

Last updated:

In 2025, Getein Biotech's return on capital employed (ROCE) was 8.99 %, a -5.23% increase from the 9.48 % ROCE in the previous year.

The Getein Biotech ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
20.45 CNY
Jan 1, 2019
23.72 CNY
Jan 1, 2020
18.86 CNY
Jan 1, 2021
19.91 CNY
Jan 1, 2022
21.14 CNY
Jan 1, 2023
11.18 CNY
Jan 1, 2024
9.48 CNY
Jan 1, 2025
8.99 CNY
The Getein Biotech ROCE history
YEARROCEYoY
8.99 %-5.23%
9.48 %-15.20%
11.18 %-47.09%
21.14 %+6.16%
19.91 %+5.56%
18.86 %-20.49%
23.72 %+16.03%
20.45 %+5.07%
19.46 %-56.28%
44.51 %+6.92%
41.63 %-15.00%
48.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc generates revenue through the sale of in vitro diagnostic reagents and diagnostic instruments. The company offers POCT reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. Diagnostic instruments include the FIA 8000 and FIA 8600 immunoquantitative analyzers, Getein 1100 and Getein 1180 fluorescence immunoquantitative analyzers, CM 400 automatic biochemical analyzer, MAGICL 6000 automatic chemiluminescence analyzer, and BHA-5000 five classification blood cell analyzer. The firm also provides testing and agency services. Products are distributed domestically and to overseas markets. The primary buyers of Getein Biotech's products include healthcare facilities, laboratories, and medical institutions within China and international markets. Domestic sales focus on the Chinese healthcare sector, while overseas markets extend to global customers seeking diagnostic solutions. The company's reagent and instrument portfolio targets hospitals, clinics, and diagnostic centers requiring reliable testing equipment and consumables. Getein Biotech's revenue streams are derived from direct sales of its diagnostic reagents and instruments, as well as service-based offerings like testing and agency services. The company's product range caters to both domestic and international healthcare providers, with a strong emphasis on in vitro diagnostic solutions for blood analysis, chemiluminescence, and biochemical testing. The firm's distribution strategy ensures its products reach medical facilities across China and internationally. Getein Biotech is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Getein Biotech's Return on Capital Employed (ROCE)

Getein Biotech's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Getein Biotech's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Getein Biotech's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Getein Biotech’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Getein Biotech stock

Return on Capital Employed (ROCE) of Getein Biotech is 8.99 % in 2025.

Return on Capital Employed (ROCE) of Getein Biotech changed from 9.48 % to 8.99 %, representing a -5.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Getein Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Getein Biotech

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Getein Biotech